脂肪性肝炎：聚（ADP-核糖）聚合酶抑制对酒精性脂肪性肝炎和非酒精性脂肪性肝炎具有保护作用。 - Suppr

Suppr

超能文献

Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.

作者信息

Ray Katrina

出版信息

Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):3. doi: 10.1038/nrgastro.2016.186. Epub 2016 Nov 16.

DOI:10.1038/nrgastro.2016.186

PMID:27848963

Abstract

摘要

相似文献

Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.

Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):3. doi: 10.1038/nrgastro.2016.186. Epub 2016 Nov 16.

PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.

J Hepatol. 2017 Mar;66(3):589-600. doi: 10.1016/j.jhep.2016.10.023. Epub 2016 Oct 29.

[Non-alcoholic fatty liver disease (NAFLD) /non-alcoholic steatohepatitis (NASH) and nutrition].

Clin Calcium. 2016 Mar;26(3):363-7.

Alcoholic steatohepatitis (ASH) causes more UPR-ER stress than non-alcoholic steatohepatitis (NASH).

Exp Mol Pathol. 2016 Oct;101(2):201-206. doi: 10.1016/j.yexmp.2016.08.002. Epub 2016 Aug 29.

Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).

Exp Mol Pathol. 2018 Aug;105(1):144-149. doi: 10.1016/j.yexmp.2018.07.005. Epub 2018 Jul 17.

Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.

J Pharmacol Exp Ther. 2018 Mar;364(3):452-461. doi: 10.1124/jpet.117.243105. Epub 2018 Jan 9.

Inhibition of Poly(ADP-Ribose) Polymerase-1 Protects Chronic Alcoholic Liver Injury.

Am J Pathol. 2016 Dec;186(12):3117-3130. doi: 10.1016/j.ajpath.2016.08.016. Epub 2016 Oct 13.

Levels of metacaspase1 and chaperones related to protein quality control in alcoholic and nonalcoholic steatohepatitis.

Exp Mol Pathol. 2015 Feb;98(1):65-72. doi: 10.1016/j.yexmp.2014.12.003. Epub 2014 Dec 16.

[Clinical and biochemical characteristics in patients with histology compatible with steatothepatitis in National Hospital Arzobispo Loayza, Lima, Peru, from 2010 to 2012].

Rev Gastroenterol Peru. 2015 Jul-Sep;35(3):236-42.

Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.

Lipids Health Dis. 2017 Dec 2;16(1):228. doi: 10.1186/s12944-017-0613-4.

引用本文的文献

Therapeutic potential of natural coumarins in autoimmune diseases with underlying mechanisms.

Front Immunol. 2024 Oct 31;15:1432846. doi: 10.3389/fimmu.2024.1432846. eCollection 2024.

Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis.

Am J Nucl Med Mol Imaging. 2024 Feb 20;14(1):41-47. doi: 10.62347/WTKQ3953. eCollection 2024.

Cross talk between bacterial and human gene networks enriched using ncRNAs in IBD disease.

Sci Rep. 2023 May 11;13(1):7704. doi: 10.1038/s41598-023-34780-x.

Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages.

Front Pharmacol. 2022 Aug 17;13:926945. doi: 10.3389/fphar.2022.926945. eCollection 2022.

The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review.

Med Gas Res. 2021 Apr-Jun;11(2):66-71. doi: 10.4103/2045-9912.311497.

CD169 Expressing Macrophage, a Key Subset in Mesenteric Lymph Nodes Promotes Mucosal Inflammation in Dextran Sulfate Sodium-Induced Colitis.

Front Immunol. 2017 Jun 26;8:669. doi: 10.3389/fimmu.2017.00669. eCollection 2017.

NAD loss, a new player in AhR biology: prevention of thymus atrophy and hepatosteatosis by NAD repletion.

Sci Rep. 2017 May 23;7(1):2268. doi: 10.1038/s41598-017-02332-9.

本文引用的文献

PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.

J Hepatol. 2017 Mar;66(3):589-600. doi: 10.1016/j.jhep.2016.10.023. Epub 2016 Oct 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验